The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve

ByLois C

May 11, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

PARIS, FRANCE / ACCESSWIRE / May possibly 5, 2022 / Pharnext SA (FR0011191287 – ALPHA) (the “Corporation”), an state-of-the-art late-clinical stage biopharmaceutical company creating novel therapeutics for neurodegenerative conditions with large unmet professional medical require, now announces that new findings from CMT&Me, a ‘real-world’ electronic life-style examine in patients with Charcot-Marie-Tooth conditions (‘CMTs’), will be presented in three poster presentations at the forthcoming Peripheral Nerve Society (‘PNS’) Yearly Assembly. The meeting is using area on May well 14-17, 2022, in-particular person at the InterContinental Lodge, in Miami, Florida, US.

CMT&Me is a real-planet electronic life-style research launched in October 2018 for 5 a long time duration, each in Europe and the US, wherever self-claimed details from clients with CMTs are collected on a typical basis. The aim of the analyze is to far better fully grasp the impression of the disorder on patients’ daily life and support them handle their situation and therapy, as effectively as elevate awareness and assess the worth of potential new solutions. This examine is managed by the enterprise Vitaccess in collaboration with client advocacy groups and key belief leaders in the subject, with the assist of Pharnext.

Particulars on poster shows at PNS are as follows:

Poster #27 (E-poster #1029)

Session:Sunday May perhaps 15, 2022, at 12.00-2.00pm

Poster #28 (E-poster #1030)

Session:Sunday May 15, 2022, at 12.00-2.00pm

Poster #2 (E-poster #1031)

Session:Tuesday Could 17, 2022, at 12.00-2.00pm

In the course of the event, Pharnext’s crew will be accessible for discussions at Booth #18, mezzanine exhibitor space.

Far more information and facts about the CMT&Me analyze can be found in this article:

About Pharnext

Pharnext is an advanced scientific-phase biopharmaceutical enterprise acquiring novel therapeutics for neurodegenerative conditions that currently deficiency healing and/or disease-modifying treatment plans. Pharnext has two direct solutions in scientific development. PXT3003 completed an worldwide Stage III trial with positive topline results for the treatment of Charcot-Marie-Tooth sickness kind 1A (‘CMT1A’) and added benefits from orphan drug position in Europe and the United States. An international pivotal Phase III review of PXT3003 in CMT1A, the Leading demo, is now ongoing. PXT864 has created encouraging Section II results in Alzheimer’s disorder and will be superior by way of partnerships. Both of Pharnext’s lead property originated from the Pleotherapy™ R&D approach. Pharnext attracts the attention of traders to the fiscal and other chance factors detailed in its economic reports. Extra facts can be identified at

Pharnext is outlined on the Euronext Expansion Inventory Exchange in Paris (ISIN code: FR0011191287).


Dr. David Horn Solomon
Chief Govt Officer
make contact [email protected]
+33 ()1 41 09 22 30

Media Relations (Worldwide)
Consilium Strategic Communications
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
[email protected]

Money Interaction (Europe)
Ghislaine Gasparetto
[email protected]
+33 ()6 21 10 49 24

Media Relations (France)
Ulysse Conversation
Bruno Arabian
[email protected]
+33 ()6 87 88 47 26
+33 ()1 81 70 96 30

Source: Pharnext

Look at resource variation on

By Lois C